Maintaining consistency with your weekly injections is vital for achieving optimal results
Even though vomiting is the distinctive feature of CVS, abdominal pain is observed in up to 80% of patients.76 Other symptoms are photophobia, sensitivity to sound, and autonomic symptoms (diaphoresis, sialorrhea, pallor, and lethargy).27 Patients also describe the behavior of drinking and gulping down and drink large quantities of water and then try to induce vomiting, which they say gives them relief (this should not be misinterpreted as a psychologic/psychiatric disorder).63 In addition, anatomic/organic causes that produce a similar symptomatology must be ruled out
Pratley RE, Amod A, Tetens Hoff S, Kadowaki T, Lingvay I, Nauck M, et al
Semaglutide has been shown to help patients lose as much as 15% of their body weight in 68 weeks of treatment
[1] A review of literature shows that the prevalence of PA is higher in Northern Europe, especially in Scandinavian countries, and among people of African descent, and that increased awareness of the disease and better diagnostic tools might play a role in apparently higher rates of incidence

For Immediate Release Contact: [email protected] MOST PATIENTS CAN CONTINUE GLP-1 ANTI-OBESITY DRUGS BEFORE SURGERY New multi-specialty guidance from surgeons, anesthesiologists, and gastroenterologists provides clarity on usage Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical guidance released today by five surgical and medical societies including the American Society for Metabolic and Bariatric Surgery (ASMBS), American Society of Anesthesiologists (ASA), American Gastroenterological Association (AGA), International Society of Perioperative Care of Patients with Obesity (ISPCOP), and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)